16th week of 2016 patent applcation highlights part 7 |
Patent application number | Title | Published |
20160106623 | DOUBLE-HEADED TRANSFUSION CONTAINER - A double-headed transfusion container comprises a body portion ( | 2016-04-21 |
20160106624 | Mixing System for Mixing Biological Specimens with Additives - A device for mixing biological specimens contained in flexible storage bags ( | 2016-04-21 |
20160106625 | MEDICATION DOSAGE SYSTEM - A medication management system according to some embodiment may include a box with multiple sections and medication packaging strips. At least two of the medication packaging strips may include medication dose envelopes serially connected together. At least two of the multiple sections in the box may include a dispensing opening allowing the medication packaging strips to be dispensed serially through the dispensing openings. The medication management system may include a tactile marker between medication dose envelopes. In some embodiments the tactile marker may include a notch in the medication packaging strip. The tactile marker may include a raised feature in the medication packaging strip. The tactile marker may be on an empty medication dose envelope positioned between and connecting two filled medication dose envelopes. | 2016-04-21 |
20160106626 | MEDICATION DOSAGE INDICATOR - Dosage log apparatuses, containers and medication dosage recording methodologies for tracking medications and dosage schedules. | 2016-04-21 |
20160106627 | Systems And Methods For Medication Adherence And Acknowledgement - Systems and methods for improving mediation adherence are provided. Various embodiments of the present invention help patients maintain their medication and other healthcare schedules and avoid costly nursing, home health care, assisted living, or nursing home alternatives whenever possible. In some embodiments, personalized recorded voice messages are used to directly contact (e.g., by telephone, VoIP, etc.) a patient when scheduled. The system can provide notifications (e.g., e-mails, text messages, automated phone calls, etc.) to a caregiver or other designated persons if the call is not acknowledged so that someone can follow up before more serious consequences arise. In addition, various reports can be generated regarding potential medication adherence and acknowledgement of the personalized voice messages. One or more rewards may be presented to the patient based on medication adherence. | 2016-04-21 |
20160106628 | DUAL CONFIGURATION BOTTLE ASSEMBLY - A bottle assembly has an open ended container and a vent assembly positionable at least in part on the rim of the container to permit venting of the container during use. The vent assembly generally comprises a vent insert and a receptacle portion releasably connectable to the vent insert. The vent insert includes an annular lip depending longitudinally within the container upon positioning of the vent assembly on the rim of the container. The annular lip has a transversely inner surface having one of a catch and a latch. The receptacle has a top and a vent tube extending downward from the top. The top of the receptacle includes a transversely outer surface having the opposite one of a catch and a latch, with the top of the receptacle being insertable into the annular lip for releasable latch and catch connection of the receptacle to the vent insert. A collar assembly generally defines a closure for the container, with the collar assembly being configured for releasable engagement with the neck of the container over the open end thereof to retain the vent assembly together with the container. | 2016-04-21 |
20160106629 | BIONIC PACIFIER - A bionic pacifier ( | 2016-04-21 |
20160106630 | Occlusion Detection for Flow Control Apparatus - There is disclosed a flow control apparatus adapted for a feeding set having a housing capable of receiving at least a portion of the feeding set, a pumping device for actiong on the feeding set to produce fluid flow in the feeding set for delivery of fluid. The pumping device has a rotor and a motor operatively connector to the rotor for rotating the rotor to act on the feeding set to produce fluid flow in the feeding set. The apparatus has a sensor arranged with respect to the pumping device to produce a signal indicative of a rotational position of the rotor, and a control circuit in communication with the sensor for receiving the sensor signal from the sensor indicative of the rotational position of the rotor and in communication with the pumping device to control operation thereof. The control circuit controls operation of the motor at a first output to rotate the rotor to produce fluid flow in the feeding set and at a second output effectively less than the first output, the control circuit monitoring the sensor signal during operation of the motor at the second output to determine occlusion in the feeding set. | 2016-04-21 |
20160106631 | BITING AND COMFORTER DEVICE FOR INFANTS - The invention concerns a biting and comforter device ( | 2016-04-21 |
20160106632 | Lithium Silicate Glass Ceramic and Glass with ZrO2 Content - Lithium silicate glass ceramics and glasses are described which can advantageously be applied to zirconium oxide ceramics in particular by pressing-on in the viscous state and form a solid bond with these. | 2016-04-21 |
20160106633 | SKIN CARE SHEET AND SKIN CARE ARTICLE - A skin care sheet comprising a nonwoven fabric; the nonwoven fabric having a break elongation of at least 250%; the nonwoven fabric comprising an embossed section and a non-embossed section defined by the embossed section, the non-embossed pattern having a pitch of 1.2 to 10.0 mm; a proportion of a total area of the embossed section occupying from 5 to 30% of a total area of the nonwoven fabric on at least one surface of the nonwoven fabric; fibers present in the nonwoven fabric having a number-average fiber diameter of 0.1 to 15.0 μm; and the fibers containing a resin having a flexural modulus of 0.5 GPa or less, as well as a skin care article comprising the sheet, are provided. | 2016-04-21 |
20160106634 | AEROSOL DEVICE BASED ON SEBUM-ABSORBING POWDER AND CALCIUM CARBONATE - The present invention relates to an aerosol device comprising a container containing: one or more propellants, and a composition comprising: one or more sebum-absorbing powders with a sebum uptake of greater than or equal to 35 ml/100 g; one or more styling powders comprising calcium carbonate; less than 10% by weight of one or more C | 2016-04-21 |
20160106635 | HIGH STRENGTH MICROCAPSULES - High strength, high integrity microcapsules containing a hydrophobic core material wherein said microcapsule walls are formed of copolymers of select monomers through a multistep oil-in-water emulsification polymerization process. | 2016-04-21 |
20160106636 | PRODUCTS CONTAINING CHARGED POLYMER COMPLEX MICROCAPSULES AND METHOD OF USE - In one aspect, the invention provides a method for treating a protein-containing surface, including applying to the surface a microcapsule suspension including droplets of a dispersed water-immiscible core phase, an aqueous continuous phase, and a wall surrounding each core phase droplet, the wall including the salt formed from at least one amphiphilic Lewis acid reactant or amphiphilic Lewis base reactant, and at least one corresponding Lewis base reactant or Lewis acid reactant. | 2016-04-21 |
20160106637 | FRAGRANCE-CONTAINING CAPSULE AND COSMETIC IN WHICH SAID CAPSULES ARE BLENDED - The present invention provides a highly stable fragrance-containing capsule. This fragrance-containing capsule is characterized in being obtained from: a core substance comprising a specified fragrance, such as 3-octanol, and an oil; and a wall material formed from one or more polymers selected from poly(alkyl(meth)acrylates) and polystyrene. | 2016-04-21 |
20160106638 | Low alcohol content disinfection foams - Disinfection foam having low levels of alcohol, comprising at least water, foaming agent, and polymeric type silver ion source, and a method of manufacturing the same. The present antimicrobial foams are especially suitable for hand sanitizer foams, shaving foams, dry cleansing foams for full body, leave on shampoos, face cleansing foams and multipurpose dry cleaning | 2016-04-21 |
20160106639 | CONTROLLED RELEASE ACTIVE AGENT CARRIER - The present invention relates to carriers for the controlled release of active agents, comprising surface reacted natural or synthetic calcium carbonate, one or more active agents, wherein said one or more active agent is associated with said surface-reacted calcium carbonate, and wherein said surface-reacted natural or synthetic calcium carbonate is a reaction product of natural or synthetic calcium carbonate with carbon dioxide and one or more acids, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source. It further relates to the preparation of loaded carriers, as well as their use in different applications. | 2016-04-21 |
20160106640 | STANNOUS SALT AND SODIUM TRIPOLYPHOSPHATE ORAL CARE COMPOSITIONS AND METHODS - Oral care compositions containing a stannous salt and sodium tripolyphosphate are provided where stannous tripolyphosphate ionic intermediates comprise less than about 1% of the compositions. Tetrasodium pyrophosphate, a methylvinyl ether-maleic anhydride copolymer and/or a silica oral polishing agent may be added for further efficacy. In a single phase blend, the oral care composition may be effectively limited to comprise less than about 10% water. In a dual-phase blend, a mixture having the stannous salt in a first phase and the sodium tripolyphosphate in a second phase may be generated from a dual chamber storage tube (with each phase provided from a separate chamber) immediately prior to dental care usage. | 2016-04-21 |
20160106641 | STABLE COMPOSITIONS FOR WHITENING TEETH AND METHODS OF USING SAME - A thickened tooth whitening composition in gel form comprises hydrogen peroxide or a hydrogen peroxide precursor, and a thickening polymer or copolymer comprising a pendant sulfonic acid group moiety, preferably hydroxyethyl acrylate/sodium acryloyldimethyltaurate copolymer. Gels in accordance with the invention exhibit an extended shelf life without requiring refrigeration or other special storage conditions. A particularly efficacious manner of method of whitening teeth comprises applying a volume of a gel in accordance with the invention onto the bristles of a toothbrush, applying a volume of a toothpaste onto the toothbrush bristles, and brushing one or more teeth to be whitened with the toothbrush bristles onto which the toothpaste and the thickened tooth whitening composition were applied for a sufficient period to cause the composition and toothpaste to mix together. | 2016-04-21 |
20160106642 | COMPOSITE PARTICLES BASED ON MINERAL UV-SCREENING AGENT AND PERLITE; COSMETIC OR DERMATOLOGICAL COMPOSITIONS CONTAINING THE SAME - The present invention relates to novel composite particles based on mineral UV-screening agent and perlite. The present invention also relates to a composition comprising, in a cosmetically acceptable medium, at least composite particles for screening out UV radiation, based on mineral UV-screening agent and perlite. The invention also relates to a cosmetic process for caring for and/or making up human keratin materials, especially bodily or facial skin or the hair, comprising at least the application, to the surface of the keratin material, of at least one composition as defined previously. The invention also relates to a non-therapeutic cosmetic process for limiting the darkening of the skin and/or improving the colour and/or uniformity of the complexion, comprising the application, to the surface of the keratin material, of at least one composition as defined previously. The invention also relates to a non-therapeutic cosmetic process for preventing and/or treating the signs of ageing of a keratin material, comprising the application, to the surface of the keratin material, of at least one composition as defined previously. | 2016-04-21 |
20160106643 | ANTIPERSPIRANT ACTIVE COMPOSITIONS AND MANUFACTURE THEREOF - An antiperspirant active composition comprising an aluminum salt, the aluminum salt (i) having an aluminum to chloride molar ratio of 0.3:1 to 3:1; and (ii) having a species of polyhydroxyoxoaluminum cation detectable it 76 ppm by | 2016-04-21 |
20160106644 | METHOD OF MANUFACTURE OF ANTIPERSPIRANT SALTS - A UHT process for the manufacture of an aqueous antiperspirant composition comprising the steps of: (i) mixing aluminium-containing antiperspirant salt, water soluble calcium salt, amino acid, and water, (ii) heating the mixture to a temperature of greater than 100° C. at a pressure of greater than 1 Bar (100,000 Pa) and (iii) restoring the mixture to ambient temperature and pressure. | 2016-04-21 |
20160106645 | Protection Against Sunburn And Skin Problems With Topical And Orally-Ingested Dosages of Zeaxanthin - Zeaxanthin is ingested orally at suitable dosages that gives skin a darker tint that emulates a healthy suntan and that reduces the severity of unwanted skin discoloration or irregularities. In tests involving adults, it was found that zeaxanthin dosages of 30 to about 80 mg per day were sufficient to induce a mild but noticeable tinting, shading, or darkening of skin color, comparable to a mild suntan, a substantial increase in the person's ability to withstand elevated levels of sun or UV exposure without any subsequent pain or discomfort, and without the subsequent peeling and flaking that characterizes sunburns, and an increased ability of reddened and sunburned skin to convert into intact skin that looks browned and healthily tanned. The topical application of zeaxanthin can further enhance the darkening of the skin and reduce the severity of unwanted skin discoloration or irregularities. | 2016-04-21 |
20160106646 | COSMETIC KIT COMPRISING EFFERVESCENT TABLET AND SKIN TONER - One aspect of the present invention relates to an effervescent tablet comprising a water-soluble lubricating agent, and a carbonated water cosmetic composition enabled to be used together therewith. One aspect of the present invention relates to an effervescent tablet comprising a crystalline #-hydroxy acid and a water-soluble lubricating agent, and a cosmetic composition using a skin toner for preventing the tablet from floating and allowing the tablet to rapidly form carbon dioxide gas in the cosmetic composition so as to maximize the visual effect and also the effect of carbon dioxide, thereby showing skin whitening, brightening and moisturizing effects and improving the pores. | 2016-04-21 |
20160106647 | COMPOSITIONS COMPRISING ZWITTERIONIC ESTER AMMONIOALKANOATES - The present invention provides compositions utilizing a zwitterionic ester ammonioalkanoate surfactant according to Formula 1 and an ingredient selected from the group consisting a surfactant other than said zwitterionic ester ammonioalkanoate surfactant, emulsifiers, conditioning agents, emollients, moisturizers, humectants, thickeners, lubricants, chelating agents, fillers, binding agents, anti-oxidants, preservatives, active ingredients, fragrances, dyes, buffering agents, exfoliates, pH adjusters, inorganic salts, solvents, viscosity controlling agents and opacifying agents, wherein the composition is substantially free of alkylamidoamine and aminoalkylamine. | 2016-04-21 |
20160106648 | COLORING AGENTS AND METHODS OF USE THEREOF - Dyes, compositions comprising dyes and methods for using the same are provided. | 2016-04-21 |
20160106649 | ANTIPERSPIRANT COMPOSITIONS - An aqueous composition comprising basic aluminium chloride salt, water soluble calcium salt, and amino acid, characterised in that the basic aluminium chloride salt is of formula Al | 2016-04-21 |
20160106650 | SOLUBILIZER FOR COSMETIC PREPARATIONS - The present invention relates to a mixture comprising (i) one or a plurality of 1,2-alkane diols with 5 through 8 carbon atoms and (ii) one or a plurality of ammonium-, sodium- or potassium-R | 2016-04-21 |
20160106651 | COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS USING NON-NATURALLY OCCURRING PROSTAGLANDINS - A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. | 2016-04-21 |
20160106652 | COSMETIC USE AS DEODORANT ACTIVE AGENT OF A SILICEOUS MATERIAL OBTAINED BY HYDROLYSIS AND CONDENSATION OF A TETRAALKOXYSILANE AND OF AN AMINOALKYL TRIALKOXYSILANE - The invention thus relates to the cosmetic use of a siliceous material that may be obtained by hydrolysis and condensation, in the presence of water, of at least one tetraalkoxysilane of formula (I) below: Si(OR | 2016-04-21 |
20160106653 | Pharmaceutical Composition for Treating Scars on the Skin, and Method for Treating Scars on the Skin Using Same - The present invention relates to a pharmaceutical composition for treating scars on the skin, comprising a mixture of botulinum toxin and air. The mixture of botulinum toxin and air according to the present invention, when injected in the dermis, may temporarily removed the elasticity of the dermis and flatten out the depressed part of the scar, and thus enables elaborate intradermic resection and increases the therapeutic effects of lasers for treating pulsed dye laser or of fractional lasers. Thus, scars on the skin can be effectively improved through a one-time operation without negatively affecting the daily lives of patients. | 2016-04-21 |
20160106654 | ADDITIVE OR SYNERGISTIC SUNSCREEN, ANTIOXIDANT, AND DNA REPAIR ENZYME COMPOSITION - A composition having an sunscreen agent, an antioxidant, and a DNA repair enzyme provides a beneficial and/or synergistically improved effect in reducing mutagenic formations, particularly in topically applied formulations. | 2016-04-21 |
20160106655 | SKIN CLEANSING COMPOSITION - Provided is a skin cleansing composition comprising the following components (A), (B), and (C): (A) from 0.5 to 40 mass % of an ether oil in a liquid state at 25° C., (B) from 0.01 to 5 mass % of a nonionic water-soluble polymer comprising cellulose as a constitutional unit selected from the group consisting of methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose, and (C) water, and 1 mass % or less of a nonionic surfactant, wherein the mass ratio of the component (B) to the component (A), (B)/(A) is from 0.001 to 5. | 2016-04-21 |
20160106656 | Cosmetic Composition and Conditioning Agent - Disclosed is a cosmetic composition comprising: a copolymer (α) or (β); a cationic surfactant; and a higher alcohol. The copolymer (α) includes a constituent unit derived from a monomer (a) acrylic acid and/or methacrylic acid, and at least one constituent unit derived from three different monomers, wherein from 50 to 100 mass % of a constituent unit derived from a vinyl monomer (A) having a carboxyl group. The copolymer (β) includes a constituent unit derived from a monomer (a) acrylic acid and/or methacrylic acid and at least one constituent unit derived from four different monomers, wherein from 50 to 100 mass % of a constituent unit derived from a vinyl monomer (A) having a carboxyl group and wherein from 50 to 100 mol % of the carboxyl groups are not neutralized. | 2016-04-21 |
20160106657 | Cosmetic Treatment with Nitric Oxide, Device for Performing Said Treatment and Manufacturing Method Therefor - A cosmetic treatment method, and a device therefor, are provided that allow for cosmetic treatment of cosmetic disorders, caused by chronological age, environmental factors, changes in physiological functions of skin, such as psoriasis, dermatitis, acne, cellulites, and viral and/or bacteriological attacks. The device comprises a nitric oxide (NO) eluting polymer arranged to contact the area to be cosmetically treated, such that a cosmetic dose of nitric oxide is eluted from said nitric oxide eluting polymer to said area. The nitric oxide (NO) eluting polymer is integrated with a carrier material, such that said carrier material, in use, regulates and controls the elution of said cosmetic dosage of nitric oxide (NO). Furthermore, a manufacturing method for said device is provided. | 2016-04-21 |
20160106658 | COMPOSITION FOR NAIL POLISH REMOVAL AND KIT FOR NAIL POLISH REMOVAL INCLUDING THE SAME - A composition for nail polish removal is disclosed. The composition for nail polish removal is applied to a nail to form a layer for nail polish removal, and then a UV gel is applied to the layer for nail polish removal or an acrylic resin is applied to the layer for nail polish removal to extend the nail. Therefore, the UV gel or the acrylic resin can be peeled off in a simple manner without the use of a special tool or the need to perform a special operation. In addition, the risk of damage to the nail can be greatly reduced. Also disclosed is a kit for nail polish removal including the composition. | 2016-04-21 |
20160106659 | POLYSILICONE BASE FOR SCAR TREATMENT - A polysilicone base for medical and cosmetic compositions includes a dimethicone fluid, a volatile cyclosiloxane, a silicone elastomer, and nanoparticulate silica. The polysilicone base may also include one or more therapeutic agents for reducing the formation and appearance of scar tissue at the site of a wound. The polysilicone base is spreadable, but does not run off of the wound site. The polysilicone base is phase-stable, in that it does not separate into phases. | 2016-04-21 |
20160106660 | USE OF AN ESSENTIAL OIL OF ORIGANUM MAJORANA, AS AN AGENT FOR TREATING AND/OR PREVENTING GREASY SKIN AND/OR THE ASSOCIATED AESTHETIC SKIN DEFECTS - The present invention relates to the cosmetic use, as an agent for treating greasy skin and/or preventing greasy or greasy-prone skin and/or the associated aesthetic skin defects, of an essential oil of | 2016-04-21 |
20160106661 | SCREENING METHOD AND SUBSTANCES FOR CONTRASTING AGING - The present invention refers to a novel in vitro method for detecting anti-senescence or pro-senescence activity of a compound, and to compounds with anti-senescence activity detected by said method, in particular to | 2016-04-21 |
20160106662 | Cocoa Butter Powdered Moisturizer - The present invention is a cocoa butter powdered moisturizer with the addition of cocoa powder serving as a stabilizing agent. The cocoa butter is grated and/or shredded into a fine granulated form and is supplemented with the stabilizing cocoa powder such that the resulting moisturizer attains a consistent, usable form. The resulting moisturizer is stable at room temperature and provides an SPF-15 level of sun protection for the skin. | 2016-04-21 |
20160106663 | PERSONAL CARE COMPOSITION AND METHOD OF MAKING - This invention relates to an improved crystallization process of hydrogenated castor oil structurant which results in (i) a dispersion having a high concentration of the structurant, and (ii) a crystal habit/form that results in a higher yield stress in the final product, imparting high stability, for a given amount structurant. In addition, the resulting personal care product is consumer desired, as less structurant residue is observed on hair after the use of the personal care product. | 2016-04-21 |
20160106665 | OCULAR DISCOMFORT - Described herein are methods and pharmaceutical formulations for improving ocular discomfort. | 2016-04-21 |
20160106666 | OPHTHALMIC FORMULATIONS OF CETIRIZINE AND METHODS OF USE - The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye. | 2016-04-21 |
20160106667 | DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTIC AGENTS - Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device. | 2016-04-21 |
20160106668 | CHOLECYSTOKININ SECRETION-PROMOTING COMPOSITION - A method is provided to promote secretion of cholecystokinin (CCK) by administering an active component. The active component includes acrylic acid and/or an unsaturated aldehyde having a main chain of 4 to 12 carbon atoms having a double bond in at least position 2 or 4, where the main chain has 4 to 9 carbon atoms when there is a double bond in only position 2, and the main chain has 9 to 12 carbon atoms when there is a double bond in only position 4. The cholecystokinin secretion-promoting composition can be used as an appetite suppressant. By adding this cholecystokinin secretion-promoting composition to food, appetite-suppressing food products can be provided. | 2016-04-21 |
20160106669 | METHOD OF THERAPEUTIC ADMINISTRATION OF DHE TO ENABLE RAPID RELIEF OF MIGRAINE WHILE MINIMIZING SIDE EFFECT PROFILE - Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (C | 2016-04-21 |
20160106670 | Novel Process - The present invention provides a process for the production of an oil in water emulsion comprising the step of a) introducing an oil phase into a mixing device by applying a positive pressure in the oil phase containing tank. | 2016-04-21 |
20160106671 | POROUS NANOPARTICLE-SUPPORTED LIPID BILAYERS (PROTOCELLS) FOR TARGETED DELIVERY AND METHODS OF USING SAME - The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery. | 2016-04-21 |
20160106672 | Liposomes Useful for Drug Delivery - The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. | 2016-04-21 |
20160106673 | AMPHIPHILIC BLOCK COPOLYMERS FOR NUCLEIC ACID DELIVERY - The present invention provides a composition comprising vesicles and encapsulated within the vesicles, nucleic acid comprising less than 1000 nucleotides, wherein the vesicles comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block. Methods of forming vesicles and methods of delivering nucleic acid, in particular, iRNA into cells, are also provided. | 2016-04-21 |
20160106674 | COLLAGEN POWDER, COMPOSITION AND USE - Collagen powder in which at least 99.5% of the particles have a maximum size of 80 microns 25% to 45% by volume of the particles have a size of more than 30 microns and 35% to 50% by volume of the particles have a size in the range of 20 to 70 microns. | 2016-04-21 |
20160106675 | COMPOSITIONS FOR MULTIPHASE, STAGGERED, OR SUSTAINED RELEASE OF AN ACTIVE SUBSTANCE - A composition having a mixture of discreet particles, each particle comprising an active substance and a coating material, the active substance being at least partially coated with the coating material. The mixture of discreet particles includes a first batch of first particles, the first particles of the first batch having a first average weight % ratio of the active substance to the coating material; and a second batch of second particles, the second particles of the second batch having a second average weight % ratio of the active substance to the coating material, the second average weight ratio being different from the first average weight ratio. | 2016-04-21 |
20160106676 | METHOD FOR THE PREPARATION OF DEGRADABLE MICROGEL PARTICLES, AND MICROGEL COMPOSITIONS THEREOF - The present application relates to an aqueous method for the preparation of microgel particles using a stimuli-responsive prepolymer | 2016-04-21 |
20160106677 | PHARMACEUTICAL COMPOSITION AND USES THEREOF - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and metformin XR (extended release), processes for the preparation thereof, and their use to treat certain diseases. | 2016-04-21 |
20160106678 | METHOD FOR DELIVERING A PHARMACEUTICAL COMPOSITION TO PATIENT IN NEED THEREOF - The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof. | 2016-04-21 |
20160106679 | TABLET WITH INCREASED DRUG LOAD OF ODANACATIB - The present invention relates to pharmaceutical tablets comprising amorphous compound I in the form of its free base or pharmaceutically acceptable salts of compound I. | 2016-04-21 |
20160106680 | Abuse Deterrent Immediate Release Formulation - The present invention relates to an immediate release orally administrable abuse-deterrent pharmaceutical formulation comprising: at least one pharmaceutically active ingredient susceptible to abuse; at least one gelling polymeric compound selected from the group consisting of: polysaccharides, sugars, sugar derived alcohols, starches, starch derivatives, cellulose derivatives, Carrageenan, pectin, sodium alginate, gellan gum, xanthan gum, poloxamer, Carbopol®, PolyOx®, povidone, hydroxypropyl methylcellulose (HPMC), hypermellose, and combinations thereof; at least one disintegrant and optionally at least one surfactant, wherein said formulation exhibit properties related to deterring the abuse, via injection or nasal inhalation when being tampered and exposed to aqueous, alcoholic, acidic and basic media. | 2016-04-21 |
20160106681 | CONTROLLED RELEASE OF VEGETARIAN PORE-SEALING CAPSULE IN STOMACH, DUODENUM, JEJUNUM, ILEUM AND COLON - A vegetarian pore-sealing capsule is provided. The pore-sealing capsule may release active substances in a gastrointestinal tract, including stomach, duodenum, jejunum, ileum and colon, under control. The pore-sealing capsule includes a capsule shell having one or more pores and a pore-sealing material for sealing at least one of the pores. When the pore-sealing capsule is located at a destination inside the gastrointestinal tract, the pore-sealing material will leave the pores. | 2016-04-21 |
20160106682 | Enteric Soft Capsules - A gel mass is provided that is useful in manufacturing enteric soft or hard capsules, or enteric tablets without coating. | 2016-04-21 |
20160106683 | TIMED, PULSATILE RELEASE SYSTEMS - A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating. Each Timed Pulsatile Release (TPR) bead population exhibits pre-determined lag-time followed by differing release characteristics. The composition and thickness of the barrier coating, composition and thickness of the lag-time coating, ratio of IR beads to one or more TPR bead populations and total dose may be varied depending on the alkalinity, pH-dependent solubility and elimination half-life of the active ingredients to achieve target PK profiles (suitable for a once or twice daily dosing regimen) in patients in need of such medications. | 2016-04-21 |
20160106684 | CASEIN COATED DRUG-LOADED IRON OXIDE NANOPARTICLES - This disclosure relates to nanoparticle drug delivery systems composed of casein (CN) coated nanoparticles, e.g., iron oxide nanoparticles coated with an inner layer and an out layer comprising the milk protein casein. In certain embodiments, drug molecules are incorporated into an inner polymeric layer coating the nanoparticles, which are subsequently coated with a casein containing outer layer, i.e., a layer-by-layer (LBL) construction. Oral administration of these casein coated nanoparticles are contemplated as experiments indicated sufficiently stability in conditions that simulate the conditions of the gut. Drugs that were loaded into the nanoparticle systems were released when the casein outer layer was gradually degraded in the presence of an intestinal protease meant to simulate conditions of the intestine. | 2016-04-21 |
20160106685 | CIPROFLOXACIN LOADED DIETHYLAMINOETHYL CELLULOSE NANOPARTICLES - This invention reports ciprofloxacin (CIP)-encapsulated polymeric nanoparticles and its antibacterial potential with a variety of gram positive and gram negative pathogenic bacteria. CIP-encapsulated nanoparticles of diethylaminoethyl cellulose (DEA-EC) are prepared by the multiple emulsion solvent evaporation method. CIP-encapsulated nanoparticles showed superior effectiveness to inhibit the growth of bacteria in-vitro. | 2016-04-21 |
20160106686 | MULTILAMINATE BACKING CONSTRUCTION - A novel backing construction for a transdermal drug delivery system is disclosed. In particular, the invention relates to a system and method for labeling a transdermal drug delivery system, wherein the backing layer contains a writable medium capable of inkless printing. | 2016-04-21 |
20160106687 | HUMAN THERAPEUTIC AGENTS - Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers. | 2016-04-21 |
20160106688 | Parenteral Administration of Tapentadol - An aqueous pharmaceutical composition adapted for parenteral administration of tapentadol or a physiologically acceptable salt thereof having a pH value of at least 5.4. | 2016-04-21 |
20160106689 | USE - The present invention relates to compositions comprising cysteamine or a derivative thereof for use in treating infections caused by yeasts or moulds. | 2016-04-21 |
20160106690 | PAIN RELIEF COMPOSITIONS, MANUFACTURE AND USES - The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions. | 2016-04-21 |
20160106691 | CHEMICAL CHAPERONINS AS NOVEL MOLECULAR MODULATORS OF BETA PROTEIN AGGREGATION PRESENT IN CONFORMATIONAL DISEASES - This invention relates to chemistry and biochemistry applied to the field of medicine and is referred to a new method of prevention and therapeutic treatment of conformational diseases (CD), in particular to amyloid origin diseases by administrating an effective amount of one or more compounds, salts, prodrugs or solvates, which are considered herein as chemical chaperonins, of Formula I, | 2016-04-21 |
20160106692 | USE OF X-RAY CONTRAST MEDIA AND RELATED COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF A FILOVIRUS INFECTION - Embodiments disclosed herein relate to certain compositions including X-ray contrast media compounds and/or certain tri-iodinated phenyl compounds and methods of using the same for preventing or treating filovirus infections. | 2016-04-21 |
20160106693 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING NEURODEGENERATIVE DISEASES WITH PARKINSONIAN SYNDROMES - A composition for treating Neurodegenerative Diseases with Parkinsonian Syndromes in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter. | 2016-04-21 |
20160106694 | PHARMACEUTICAL COMPOSITIONS COMPRISING DROXIDOPA - The present invention provides combinations of droxidopa and one or more further pharmaceutically active compounds, said further compounds preferentially being selected from the group of COMT inhibiting compounds, cholinesterase inhibiting compounds, and monoamine oxidase inhibiting compounds. The invention further provides methods of treating conditions, such as orthostatic hypotension, comprising administering the combinations. | 2016-04-21 |
20160106695 | PETROSELINIC ACID OR A COMBINATION OF ACTIVE INGREDIENTS COMPRISING AT LEAST PETROSELINIC ACID FOR PROMOTING WEIGHT LOSS AND/OR WEIGHT MAINTENANCE - The present invention relates to the field of weight management and obesity. It concerns petroselinic acid or a combination of active ingredients including at least petroselinic acid and at least one compound chosen from zinc, taurine, one of the salts of same, lycopene and the mixtures thereof, and preferably at least taurine or zinc gluconate and, more preferably still, at least taurine and zinc gluconate, as a drug for oral administration or as a functional food intended to promote weight loss and/or weight maintenance in a human being and/or animal, or indeed intended to fight obesity. | 2016-04-21 |
20160106696 | PHARMACEUTICAL PRODUCT, MEDICAL FOOD OR DIETARY SUPPLEMENT FOR PREVENTING CANCER AND INFLAMMATORY DISEASES - The present invention relates to cancer therapy by administering a specific dietary composition. Especially the invention relates to a pharmaceutical, medical food or dietary supplement composition comprising the combination of the following three active ingredients: hydroxytyrosol, fish oil EPA/DHA and curcumin. The pharmaceutical composition is useful in the treatment or prevention of cancer, especially breast cancer. | 2016-04-21 |
20160106697 | METHODS FOR MAKING RETINOIDS AND USES THEREOF - Described herein are methods for making retinoids. Also described herein are retinoids and methods of use thereof. | 2016-04-21 |
20160106698 | Compositions And Methods Of Use Of Phorbol Esters - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects. | 2016-04-21 |
20160106699 | Oral pharmaceutical composition containing combination of PPARa and a HMG-CoA reductase inhibitor - Oral pharmaceutical composition containing, in the same pharmaceutical form, effective amounts of a HMG-CoA reductase inhibitor derivative and of PPARα, especially fenofibrate. Also described is the use of some inactive ingredients which allow to improve the dissolution and/or bioavailability of the drugs from the said composition. | 2016-04-21 |
20160106700 | Pharmaceutical Formulation for Histone Deacetylase Inhibitors - A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula | 2016-04-21 |
20160106701 | METHOD FOR PREVENTING AND/OR TREATING HAIRY WART DISEASE - Provided is a novel method for preventing and/or treating hairy wart disease which is a hoof and leg disease of ungulates. The method is carried out by administering an isothiocyanic acid ester such as allyl isothiocyanate to a hoof of an ungulate. Examples of ungulates targeted for application of the present invention include cows such as dairy cows as well as sheep, pigs and horses. | 2016-04-21 |
20160106702 | METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs - The present invention is directed to methods of treating, preventing, suppressing and/or inhibiting urological disorders such as urinary incontinence including stress urinary incontinence and pelvic-floor disorders by administering a SARM compound of the invention. | 2016-04-21 |
20160106703 | FUMAGILLOL TYPE COMPOUNDS AND METHODS OF MAKING AND USING SAME - The disclosure provides a fumagillol type compound and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided. | 2016-04-21 |
20160106704 | METHODS FOR DELIVERING CROMOLYN - Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and blister packs and kits comprising cromolyn are described. | 2016-04-21 |
20160106705 | CANNABIS EXTRACTS AND METHODS OF PREPARING AND USING SAME - The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from | 2016-04-21 |
20160106706 | METHOD OF DELIVERING AN ANTI-CANCER AGENT TO A CELL - There is provided a delivery vehicle comprising an anti-cancer agent together with a conjugate of a delivery agent containing a free aldehyde and a flavonoid, having the delivery agent conjugated at the C6 and/or the C8 position of the A ring of the flavonoid. The resulting delivery vehicles may be used to deliver an anti-cancer agent to a cell. | 2016-04-21 |
20160106707 | METHOD FOR OBTAINING A STABLE GEL OF HYALURONIC ACID AND OF A FREE FORM OF VITAMIN C AND/OR A SALT THEREOF - The invention relates to a process for producing an aqueous gel comprising hyaluronic acid, vitamin C, and a stabilizing agent selected from the metabisulfites. According to the invention, such a process comprises the steps of a) preparing a mixture comprising crosslinked or non-crosslinked hyaluronic acid and/or a salt thereof with a molar mass of between 1000 Da and 10 MDa, from 0.1 to 20.0% by weight of vitamin C in its acid form, or its equivalent in ascorbate derived from a vitamin C salt, from 0.01 to 1.00% by weight of a stabilizing agent selected from the metabisulfites, and an aqueous solution added so that the hyaluronic acid content is between 0.01 and 100 mg/ml, so as to form a hydrogel, and b) degassing the mixture before the hydrogel being formed is completely swollen. | 2016-04-21 |
20160106708 | USE OF ANTIOXIDANTS FOR THE TREATMENT OF COGNITIVE AND BEHAVIOURAL DISORDERS IN INDIVIDUALS WITH FRAGILE X SYNDROME - The invention relates to the use of antioxidants such as, ascorbic acid (Vitamin C), Tocopherol (Vitamin E), vitamin A and polyphenols, for the treatment of cognitive and behavioural disorders in patients with Fragile X syndrome. Specifically, the invention relates to the use of said antioxidants in a pre-determined concentration in a therapeutic doses, in order to obtain the greatest amount of antioxidants possible in all the tissues of the organism, so as to eliminate the excess free radicals produced in the cells and to treat the aforementioned cognitive and behavioural disorders in patients with Fragile X syndrome. | 2016-04-21 |
20160106709 | VITAMIN C AND CHROMIUM-FREE VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING AN NFKB-MEDIATED CONDITION OR DISEASE - Provided herein is a pharmaceutical composition comprising vitamin C and chromium-free vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Also provided herein is a chromium-free pharmaceutical composition comprising vitamin C and vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Further provided herein is a method of treating, preventing, or managing an NFκB-mediated condition, disorder, or disease, comprising administering to the subject a therapeutically effective amount of vitamin C and chromium-free vitamin K. | 2016-04-21 |
20160106710 | WOUND HEALING VIA AUTOLOGOUS STEM CELL MOBILIZATION - The present invention relates to the field of wound healing. More specifically, the present invention provides methods and compositions useful for improved wound healing via autologous stem cell mobilization. In one embodiment, a method for improving wound healing in a patient comprises administering to the patient a therapeutically effective amount of a stem cell mobilizer and a low dose of an immunosuppressive agent. | 2016-04-21 |
20160106711 | 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation - Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using diaryloxindole compounds are described. | 2016-04-21 |
20160106712 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES - The invention relates to fatty acid COX inhibitor derivatives; compositions comprising an effective amount of a fatty acid COX inhibitor derivative; and methods for treating or preventing a metabolic, autoimmune inflammatory, or neurodegenerative disorder comprising the administration of an effective amount of a fatty acid COX inhibitor derivative. | 2016-04-21 |
20160106713 | NITRIC OXIDE SCAVENGERS - Therapeutic compositions capable of removing excess nitric oxide are provided. The therapeutic compositions include nitronyl nitroxide monoradicals, B12 derivatives, flavonoid derivatives, the like and combinations thereof. The therapeutic compositions can be utilized in a number of suitable applications, such as to prevent or treat intradialytic hypotension during dialysis. | 2016-04-21 |
20160106714 | AQUEOUS-BASED METRONIDAZOLE GEL FORMULATIONS - The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis. | 2016-04-21 |
20160106715 | METHODS TO INHIBIT INFECTION DURING WOUND HEALING WITH TOPICAL COMPOSITIONS INCLUDING AMINO ACIDS - A method that inhibits infection during wound healing by topical application of a single composition, which contacts a wound for a period of time to initiate wound healing. The single composition may include a mixture of all or some of the amino acids including: histidine monohydrochloride monohydrate; isoleucine; leucine; lysine acetate; methionine; phenylalanine; threonine; tryptophan; valine; alanine; arginine acetate; aspartic acid; glutamine; glycine; proline; serine; and tyrosine, which may provide aqueous mixtures of a range of osmolarities or a powdered mixture of amino acids. The single composition may also include any of a carbohydrate, a mixture of fatty acids, vitamins, and mineral nutrients, and another mixture of amino acid derivatives and preservatives. The number of moles of the carbohydrate is less than and proportional to a sum of the number of moles of any mixture of amino acids in the single composition. | 2016-04-21 |
20160106716 | Solid Dosage Forms of Bendamustine - In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable or oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5. | 2016-04-21 |
20160106717 | CAI-BASED SYSTEMS AND METHODS FOR THE LOCALIZED TREATMENT OF UVEITIS - This invention relates to the treatment of uveitis, in particular posterior infectious uveitis. In specific embodiments, the invention provides for methods of treating uveitis and/or infectious uveitis comprising administration of a sustained-release system containing 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide) and optionally a glucocorticoid. In one embodiment, the glucocorticoid is dexamethasone. In another embodiment, the sustained-release system comprises a polymer such as e.g. polylactic-coglycolic acid. | 2016-04-21 |
20160106718 | CAI-BASED SYSTEMS AND METHODS FOR THE LOCALIZED TREATMENT OF UVEITIS - This invention relates to the treatment of uveitis, in particular posterior infectious uveitis. In specific embodiments, the invention provides for methods of treating uveitis and/or infectious uveitis comprising administration of a sustained-release system containing 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide) and optionally a glucocorticoid. In one embodiment, the glucocorticoid is dexamethasone. In another embodiment, the sustained-release system comprises a polymer such as e.g. polylactic-coglycolic acid. | 2016-04-21 |
20160106719 | Transplantation Adjuvant in Cell Therapy Using Neural Progenitor Cells - The present invention provides a transplantation adjuvant for neural progenitor cells containing valproic acid and/or zonisamide as an active ingredient. | 2016-04-21 |
20160106720 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT - The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as methods of modulating bone processes, and methods of treating bone-related disease, disorders, and symptoms thereof. | 2016-04-21 |
20160106721 | HUMAN THERAPEUTIC AGENTS - Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers. | 2016-04-21 |
20160106722 | HUMAN THERAPEUTIC AGENTS - Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers. | 2016-04-21 |
20160106723 | METHODS TO SENSE AND TREAT SUBCLINICAL SKIN DAMAGE - A method of sensing and removing subclinical, precancerous cells from skin wherein the unblemished skin is not being treated for AK, fine lines or clinical wrinkles and is not chronically exposed to sun or UV radiations, the method comprising topically applying to skin of a patient a composition essentially comprising of an TLR7 agonist agent, Imiquimod in an amount effective to induce a cellular immune response in the skin resulting in the sensing and removal of subclinical, atypical keratinocytes by erythema, scaling, crusting, or combinations thereof. | 2016-04-21 |